Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America

Jialun Zhou, Antoine Jaquet, Emmanuel Bissagnene, Beverly Musick, Kara Wools-Kaloustian, Nicola Maxwell, Andrew Boulle, Firas Wehbe, Daniel Masys, Jeniffer Iriondo-Perez, Jay Hemingway-Foday, Matthew Law*

*Corresponding author for this work

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Methods. Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region. Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine. Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.

    Original languageEnglish (US)
    Article number5
    JournalJournal of the International AIDS Society
    Volume15
    Issue number1
    DOIs
    StatePublished - Jan 31 2012

    Fingerprint

    Central America
    South America
    Africa South of the Sahara
    Anemia
    HIV
    Central Africa
    Southern Africa
    Eastern Africa
    Hemoglobins
    Western Africa
    Therapeutics
    Acquired Immunodeficiency Syndrome
    Databases
    Central Asia
    Zidovudine
    CD4 Lymphocyte Count
    Proportional Hazards Models

    ASJC Scopus subject areas

    • Public Health, Environmental and Occupational Health
    • Infectious Diseases

    Cite this

    Zhou, Jialun ; Jaquet, Antoine ; Bissagnene, Emmanuel ; Musick, Beverly ; Wools-Kaloustian, Kara ; Maxwell, Nicola ; Boulle, Andrew ; Wehbe, Firas ; Masys, Daniel ; Iriondo-Perez, Jeniffer ; Hemingway-Foday, Jay ; Law, Matthew. / Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. In: Journal of the International AIDS Society. 2012 ; Vol. 15, No. 1.
    @article{bc3c29e14d714189b913567aba5dc75b,
    title = "Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America",
    abstract = "Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Methods. Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region. Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45{\%} of Western Africa patients, 29{\%} of Eastern Africa patients, 21{\%} of Southern Africa patients, 36{\%} of Central Africa patients, 15{\%} of patients in Asian-Pacific and 14{\%} of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine. Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.",
    author = "Jialun Zhou and Antoine Jaquet and Emmanuel Bissagnene and Beverly Musick and Kara Wools-Kaloustian and Nicola Maxwell and Andrew Boulle and Firas Wehbe and Daniel Masys and Jeniffer Iriondo-Perez and Jay Hemingway-Foday and Matthew Law",
    year = "2012",
    month = "1",
    day = "31",
    doi = "10.1186/1758-2652-15-5",
    language = "English (US)",
    volume = "15",
    journal = "Journal of the International AIDS Society",
    issn = "1758-2652",
    publisher = "International AIDS Society",
    number = "1",

    }

    Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. / Zhou, Jialun; Jaquet, Antoine; Bissagnene, Emmanuel; Musick, Beverly; Wools-Kaloustian, Kara; Maxwell, Nicola; Boulle, Andrew; Wehbe, Firas; Masys, Daniel; Iriondo-Perez, Jeniffer; Hemingway-Foday, Jay; Law, Matthew.

    In: Journal of the International AIDS Society, Vol. 15, No. 1, 5, 31.01.2012.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America

    AU - Zhou, Jialun

    AU - Jaquet, Antoine

    AU - Bissagnene, Emmanuel

    AU - Musick, Beverly

    AU - Wools-Kaloustian, Kara

    AU - Maxwell, Nicola

    AU - Boulle, Andrew

    AU - Wehbe, Firas

    AU - Masys, Daniel

    AU - Iriondo-Perez, Jeniffer

    AU - Hemingway-Foday, Jay

    AU - Law, Matthew

    PY - 2012/1/31

    Y1 - 2012/1/31

    N2 - Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Methods. Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region. Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine. Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.

    AB - Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Methods. Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region. Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine. Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.

    UR - http://www.scopus.com/inward/record.url?scp=84862802799&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84862802799&partnerID=8YFLogxK

    U2 - 10.1186/1758-2652-15-5

    DO - 10.1186/1758-2652-15-5

    M3 - Article

    C2 - 22289654

    AN - SCOPUS:84862802799

    VL - 15

    JO - Journal of the International AIDS Society

    JF - Journal of the International AIDS Society

    SN - 1758-2652

    IS - 1

    M1 - 5

    ER -